News | November 13, 2023
Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr
European operations' revenue grew 58.4% to Rs 599.7 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
